Breviflorex®

Management of glaucoma centers on two linked problems: raised or poorly tolerated intraocular pressure (IOP), and a pressure-independent neurodegeneration of retinal ganglion cells (RGCs) that continues even when IOP is controlled. On the pressure side, Breviflorex components inhibit aqueous humour production (carbonic anhydrase II/IV inhibition, and β2-adrenoceptor-cAMP blockage), tissue fibrosis/TM cell loss via blockage of TGF-β2/SMAD3 signaling. On the pressure-independent neurodegeneration side, stressed RGCs, astrocyte/Müller glial reactivity, excitotoxicity and loss of retrograde neurotrophic transport (BDNF/TrkB, NGF) drive neuroinflammation which amplifies axonal injury. Breviflorex botanicals therefore offer neurotrophic support via Yamanaka factors gene upregulation (Oct4, Sox2, and Klf4), α2-adrenergic neuroprotection, Nrf2 activation, and naturally-occurring antioxidants/anti-inflammation. Breviflorex therefore slows and potentially reverses RGC death and optic nerve cupping.